Roivant Sciences Ltd. (ROIV)

Roivant Sciences trailed consensus on both the top and bottom line in the first fiscal quarter of 2026, reported August 6, 2026, as revenue of $1.4 million trailed the $2.1 million estimate (-30%) and adjusted EPS of -$0.33 trailed the -$0.30 estimate (-10%). Revenue fell 34% year over year to about $1.4 million (down from roughly $2.2 million a year ago), while gross profit came in at around $1.2 million and gross margin was about 80%. Operating results remained deeply negative, with operating income of roughly -$366.0 million, and net income improved 15% year over year to about -$189.8 million (from roughly -$223.4 million a year ago). For the next period, consensus calls for EPS of USD -0.41 on revenue of USD 3.3 million.